| Ytd | -88.03% | |
| 1y | -98.03% |
| Open | 4.06 | Prev Close | 4.19 | Low | 4.06 | High | 4.70 | Mkt Cap | 2.33M |
| Vol | 82.81K | Avg Vol | 79.74K | EPS | -15.29 | P/E | -0.30 | Forward P/E | -0.43 |
| Beta | -0.88 | Short Ratio | 0.02 | Inst. Own | 10.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 10.52 | 200-d Avg | 43.06 | 1yr Est | 7.50 |
GNPX News
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday'
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday'
Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validat
Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecent
The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Arou
Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Surviv
Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Te
Strengthens Patent Estate and Expands Protection in Another Target Market AUSTIN, Texas, April 30, 2
Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Te
AUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GN
Research on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentia
TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy REQORSA Induced Apop
Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report)
Genprex (NASDAQ: GNPX - Get Free Report) will likely be issuing its resultson Friday, March 27th. An
Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene Therap
AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GN
Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'
Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentr
A Republican U.S. Representative made multiple trades in 2025, including Cracker Barrel and a little
Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and S
Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy i
The list of the top 10 members of Congress for 2025 investment portfolio gains. Where did Marjorie T
During the session on Thursday, 461 stocks hit new 52-week lows.
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durabil
Thursday's session saw 337 companies set new 52-week lows.